Skip to main content

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.

Oppenheimer 33rd Annual Healthcare Conference:

Format:Fireside chat and one-on-one meetings
Date:March 13-15, 2023
Fireside chat:March 13, 10:00am ET
Presenter:Spiro Rombotis

35th Annual Roth Conference:

Location:Dana Point, CA
Format:Fireside chat and one-on-one meetings
Date:March 12-14, 2023
Fireside chat:March 13, 3:00pm PT
Presenter:Paul McBarron

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit


Company:Paul McBarron, (908) 517-7330,
Investor Relations:Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681,

© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.